Is ZEJULA Right for You?
Whether you are considering a maintenance treatment or simply wondering what the next step will be after chemotherapy, your doctor can help you find the right choice for you.
ZEJULA may be right for you if you are a woman diagnosed with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has1
- Previously been treated with 2 or more courses of platinum-based chemotherapy, and
- Responded (completely or partially) to the most recent treatment
ZEJULA offers more time without your cancer recurring, regardless of BRCA status1
One of the ways ZEJULA was studied was by looking at information gathered during the clinical trial about how long women lived without progression. One analysis estimated the likelihood of the progression during specific time points, such as 2 years after beginning therapy. This estimated how likely it was that women participating in the study were still receiving ZEJULA or placebo at 2 years.*2,3
After 2 years of treatment with ZEJULA, it was estimated that†
of women with an inherited BRCA mutation would not experience progression of their recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with 16% who did not receive ZEJULA3
of women without an inherited BRCA mutation would not experience progression of their recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with 12% who did not receive ZEJULA3
Estimated long-term PFS of 24 months.
*Patients in the study whose cancer progression status was unknown were not included in this analysis.2
†Long-term information about overall survival is not yet available.2
Listen to women like you talk about their maintenance treatment with ZEJULASee their stories
Find resources that may help you access and pay for ZEJULAGet Access and Support
Get support whether you're already taking ZEJULA or still deciding if it's right for youSign up now
References: 1. ZEJULA [package insert]. Waltham, MA: GSK, Inc.; October 2019. 2. Mirza MR, Monk BJ, Herrstedt J, et al; for the ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164. 3. Data on file. TESARO, Inc.